We have located links that may give you full text access.
Modified biomolecule as potential vehicle for buccal delivery of doxepin.
Therapeutic Delivery 2016 October
AIM: Doxepin is a traditional tricyclic antidepressant with analgesic and anesthetic properties when applied topically to the mucosa. Doxepin is one approach in treating insomnia and depression in Parkinson's disease. Patients with Parkinson's disease suffer difficulties in swallowing. Therefore, it was the aim of this study to develop a buccal-adhesive delivery system.
METHODS: Pectin was modified with cysteine. Stability assays in form of disintegration assay according to the Ph.Eur were performed. Furthermore, bioadhesiveness on buccal mucosa was investigated incorporating the drug doxepin.
RESULTS: The adhesiveness was improved 1.4-fold and revealed a sustained release over 3 h.
CONCLUSION: Taking these findings into account, the modifications render this designed excipient fruitful for buccal delivery.
METHODS: Pectin was modified with cysteine. Stability assays in form of disintegration assay according to the Ph.Eur were performed. Furthermore, bioadhesiveness on buccal mucosa was investigated incorporating the drug doxepin.
RESULTS: The adhesiveness was improved 1.4-fold and revealed a sustained release over 3 h.
CONCLUSION: Taking these findings into account, the modifications render this designed excipient fruitful for buccal delivery.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app